BriaCell Therapeutics Corp. Common Shares (BCTX)

About BCTX

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Website

briacell.com/

Fundamentals

1-day range

$3.6$3.76

Market cap

$30.01M

P/E (trailing)

—

P/E (forward)

-9.56

EPS (trailing)

$-17.14

Dividend yield

—

Beta

1.50

Avg. volume

308.8K

Dividend pay date

January 2, 2020

BriaCell Therapeutics Corp. Common Shares Competitors

Chosen by industry and closest market cap.

• BCTX

  BriaCell Therapeutics Corp. Common Shares

  $3.73

  ▲ 0.54%
  Market cap $30.01MP/E —
  $3.68$20.4
• ACTU

  Actuate Therapeutics Inc. Common stock

  $1.67

  ▼ 1.18%
  Market cap $29.43MP/E —
  $0.9$9.22
• MIRA

  MIRA Pharmaceuticals Inc. Common Stock

  $0.75

  ▼ 2.60%
  Market cap $28.50MP/E —
• GRCE

  Grace Therapeutics Inc. Common Stock

  $2.13

  ▼ 1.39%
  Market cap $28.44MP/E —
  $1.79$5.18
• RMTI

  Rockwell Medical Inc. Common Stock

  $8.22

  ▲ 6.06%
  Market cap $28.26MP/E —
  $4.89$21
• KYNB

  Kyntra Bio Inc. Common Stock

  $8.02

  ▲ 1.26%
  Market cap $28.26MP/E —
  $6.32$12.6
• ABVC

  ABVC BioPharma Inc. Common Stock

  $0.8251

  ▲ 3.66%
  Market cap $27.09MP/E —
  $0.7069$3.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• In today's session, these stocks are experiencing unusual volume.
  ChartMill · 8/25/2026
• BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone
  benzinga · 8/24/2026
• BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone
  Benzinga · 8/24/2026
• BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
  Yahoo · 8/5/2026
• BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer
  Benzinga · 8/5/2026

Institutional Ownership

March 31, 2026

Total shares held

386.8K

Total value held

$1.62M

Institutional holders

16